Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

and objective response rates of 44% to 60% with cemiplimab (Libtayo) and 34% with pembrolizumab (Keytruda) for patients with ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid tumors. Recent updates include ...

Optimal Treatment Response: Three patients achieved partial response ... or in combination with the second-line immunotherapy Libtayo. The company aims to explore further indications and potential ...